Prognosis and Planning for the Future
At a Glance
FTD-ALS often progresses faster than frontotemporal dementia or ALS alone, with median survival around three years from symptom onset in studies, but individual timelines vary. Early advance care planning, palliative care, and communication planning help preserve the patient’s choices.
Facing a diagnosis of FTD-ALS means navigating a disease that moves more quickly than either “pure” FTD or “pure” ALS. Because this condition affects both the body’s ability to move and the brain’s ability to process information, the window for making complex medical and legal decisions is often narrower than families expect [1][2].
Understanding the Timeline
While every person’s journey is unique, research provides a general framework for what to expect. FTD-ALS is considered a highly aggressive disease. In systematic reviews, median survival from symptom onset is often around 3.0 years [3][4]. However, these estimates vary with diagnostic criteria, and a median is not an individual prediction or a deadline. A clinician should help translate population data into your situation.
Several factors can influence this timeline:
- Symptom Onset: In one cohort, people whose disease began with motor weakness (motor-onset) typically had a shorter survival (median 2.7 years) compared to those who first experienced personality or language changes (cognitive-onset, median 4.4 years) [2].
- The Bulbar Factor: If the disease starts in the muscles used for swallowing and speaking (bulbar-onset), the progression is generally faster [4][1].
- Genetic Influence: For those with the C9orf72 repeat expansion, the FTD-ALS presentation specifically has a median survival of approximately 3.0 years in some studies [4].
- Common Complications: Respiratory failure is a leading cause of death in ALS, while aspiration and pneumonia may contribute or overlap [5].
Prioritizing Advanced Care Planning (ACP)
Because executive dysfunction (difficulty with planning and reasoning) can appear early, it is vital to complete legal and medical documentation as soon as possible [6]. Waiting until a crisis occurs often means the patient may no longer have the “capacity” to sign documents or make their wishes known [7].
The Essential Checklist:
(Note: Advance directives and healthcare proxy terminology varies heavily by jurisdiction. Seek local legal or social-work assistance).
- Durable Power of Attorney for Healthcare: Designate a proxy or surrogate—someone who knows your loved one’s values and can make medical decisions if they cannot [8].
- Advance Directive: Document specific preferences regarding life-sustaining treatments, such as CPR, permanent ventilation (tracheostomy), and artificial nutrition (PEG tube) [9][10]. Create a values-based planning worksheet covering acceptable tradeoffs for NIV, gastrostomy, and hospital transfers.
- Financial Power of Attorney: Ensure someone is legally authorized to manage bank accounts and bills as cognitive decline progresses, as a healthcare proxy does not automatically cover finances.
- Communication Plan: Since language can be lost, established “yes/no” signals or using AAC devices while the patient has capacity ensures their voice remains part of the conversation [10][11]. Share copies of these documents with the clinic, caregivers, and emergency services.
Integrating Palliative and Hospice Care
Palliative care is not just for the end of life; it is a “specialty layer” of support that should begin at the time of diagnosis [12].
- Palliative Care: Focuses on “goals of care” and symptom relief (such as managing anxiety, pain, or excessive saliva) while the patient is still pursuing disease-slowing treatments like Riluzole [10][9].
- Hospice Care: Hospice eligibility and coverage are jurisdiction-dependent. While it typically begins when the focus shifts to comfort and the prognosis is estimated at six months or less, hospice can sometimes continue selected treatments, equipment like NIV, and symptom-directed care when consistent with goals; enrollment does not automatically require stopping every disease-directed medication [13]. In FTD-ALS, hospice teams help manage the complex transition to “comfort-only” care, providing equipment and medications to ensure the patient is not in pain or struggling to breathe at home [12][13].
The goal of advanced care planning is to remove the “guesswork” for caregivers. Knowing exactly what your loved one would have wanted allows you to focus on being present with them, rather than struggling with agonizing decisions during a medical crisis [7][10].
Common questions in this guide
What is the typical life expectancy for someone with FTD-ALS?
Does the first symptom affect the prognosis of FTD-ALS?
Why should advance care planning begin soon after an FTD-ALS diagnosis?
Which legal and medical documents are important in FTD-ALS?
Is palliative care only for the final stage of FTD-ALS?
When might hospice care be appropriate for FTD-ALS?
How can someone with FTD-ALS communicate wishes if speech or language is lost?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on the current combination of motor and cognitive symptoms, what is the most realistic window of time we have to finalize legal and medical documents while my loved one still has capacity?
- 2.Does our current clinic incorporate palliative care specialists who can help with symptom management and advance care planning early in the disease?
- 3.How will we formally assess decision-making capacity if my loved one develops significant language impairment or severe apathy?
- 4.Can you explain how our specific clinical presentation (like bulbar-onset symptoms) influences the prognosis in our case?
- 5.What is the local procedure for transitioning to home-based hospice, and how do we ensure the hospice team is familiar with ALS-specific equipment like NIV?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Motor neuron disease beginning with frontotemporal dementia: clinical features and progression.
Gromicho M, Kuzma-Kozakiewicz M, Szacka K, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2021; (22(7-8)):508-516 doi:10.1080/21678421.2021.1910309.
PMID: 34229542 - 2
Phenotypic variability in ALS-FTD and effect on survival.
Ahmed RM, Devenney EM, Strikwerda-Brown C, et al.
Neurology 2020; (94(19)):e2005-e2013 doi:10.1212/WNL.0000000000009398.
PMID: 32277059 - 3
Survival in Frontotemporal Dementia Phenotypes: A Meta-Analysis.
Kansal K, Mareddy M, Sloane KL, et al.
Dementia and geriatric cognitive disorders 2016; (41(1-2)):109-22 doi:10.1159/000443205.
PMID: 26854827 - 4
Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.
Glasmacher SA, Wong C, Pearson IE, Pal S
JAMA neurology 2020; (77(3)):367-376 doi:10.1001/jamaneurol.2019.3924.
PMID: 31738367 - 5
Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia.
Cortés-Vicente E, Turon-Sans J, Gelpi E, et al.
Dementia and geriatric cognitive disorders 2018; (45(3-4)):220-231 doi:10.1159/000488528.
PMID: 29886477 - 6
Cognitive and behavioural impairment in amyotrophic lateral sclerosis.
Pender N, Pinto-Grau M, Hardiman O
Current opinion in neurology 2020; (33(5)):649-654 doi:10.1097/WCO.0000000000000862.
PMID: 32833751 - 7
Amyotrophic lateral sclerosis: a clinical review.
Masrori P, Van Damme P
European journal of neurology 2020; (27(10)):1918-1929 doi:10.1111/ene.14393.
PMID: 32526057 - 8
Cognitive and Behavioral Manifestations in ALS: Beyond Motor System Involvement.
Rusina R, Vandenberghe R, Bruffaerts R
Diagnostics (Basel, Switzerland) 2021; (11(4)) doi:10.3390/diagnostics11040624.
PMID: 33808458 - 9
Palliative Care Consults in an Inpatient Setting for Patients With Amyotrophic Lateral Sclerosis.
Mehta AK, Jackson NJ, Wiedau-Pazos M
The American journal of hospice & palliative care 2021; (38(9)):1091-1098 doi:10.1177/1049909120969959.
PMID: 33111546 - 10
Palliative care principles in ALS.
Shoesmith C
Handbook of clinical neurology 2023; (191()):139-155 doi:10.1016/B978-0-12-824535-4.00007-0.
PMID: 36599506 - 11
The involvement of language-associated networks, tracts, and cortical regions in frontotemporal dementia and amyotrophic lateral sclerosis: Structural and functional alterations.
Tahedl M, Tan EL, Chipika RH, et al.
Brain and behavior 2023; (13(11)):e3250 doi:10.1002/brb3.3250.
PMID: 37694825 - 12
Top Ten Tips Palliative Care Clinicians Should Know About Amyotrophic Lateral Sclerosis.
Everett EA, Pedowitz E, Maiser S, et al.
Journal of palliative medicine 2020; (23(6)):842-847 doi:10.1089/jpm.2020.0046.
PMID: 32101493 - 13
Clinical Changes in Patients With Amyotrophic Lateral Sclerosis Admitted to a Home Care Program.
Mercadante S, Petronaci A, Casuccio A
Journal of pain and symptom management 2026; (71(4)):560-566 doi:10.1016/j.jpainsymman.2025.12.026.
PMID: 41577086
This page is for informational purposes only and does not constitute medical advice. Prognosis, decision-making capacity, legal documents, palliative care, and hospice eligibility should be discussed with the patient’s clinical team and local legal or social-work professionals.
Get notified when new evidence is published on Frontotemporal dementia with motor neuron disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.